Please assess the completion status of the following clinical trial:

Trial Title: Use of NPSP558 in the Treatment of Hypoparathyroidism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Patients who meet all of the following inclusion criteria can be enrolled and potentially randomized into this study:~* Adult males or females 18 to 85 years of age (prior to screening)~* History of hypoparathyroidism for ≥ 18 months~* Requirement for vitamin D metabolite/analog therapy with calcitriol ≥0.25 μg per day or alphacalcidol ≥0.50 μg per day prior to randomization. Requirement for supplemental oral calcium treatment ≥ 1000 mg per day over and above normal dietary calcium intake~* Serum thyroid function tests within normal laboratory limits at screening~* Serum magnesium levels within laboratory normal limits~* Serum 25-hydroxyvitamin D \[25(OH)D\] level ≤ 1.5-fold the laboratory upper limit of normal~* Creatinine clearance \> 30 mL/min on two separate measurements OR creatinine clearance \> 60 mL/min AND serum creatinine \< 1.5 mg/dL~* With regard to female patients: women who are postmenopausal and women who are surgically sterilized can be enrolled. Women of childbearing potential must have a negative pregnancy test at Randomization and be willing to use two medically acceptable methods of contraception for the duration of the study.~Exclusion Criteria~Patients who have any of the following during the screening visit are not eligible for enrollment in this study:~* Known history of hypoparathyroidism resulting from an activating mutation in the CaSR gene or impaired responsiveness to PTH (pseudohypoparathyroidism)~* Any disease that might affect calcium metabolism or calcium-phosphate homeostasis other than hypoparathyroidism, such as active hyperthyroidism, Paget's disease, insulin dependent diabetes mellitus (IDDM) or poorly controlled Type II diabetes mellitus (HbA1C \> 8%), severe and chronic cardiac, liver or renal disease, Cushing's syndrome, neuromuscular disease such as rheumatoid arthritis, myeloma, pancreatitis, malnutrition, rickets, recent prolonged immobility, active malignancy, primary or secondary hyperparathyroidism, a history of parathyroid carcinoma, hypopituitarism, acromegaly, or multiple endocrine neoplasia types I and II~* Patients with a history of thyroid cancer must be documented to be disease-free for a period of at least 5 years~* Patients dependent on regular parenteral calcium infusions (eg calcium gluconate) to maintain calcium homeostasis~* Patients that have undergone gastric resection or have active peptic ulcer disease requiring medical therapy~* Use of prohibited medications such as loop and thiazide diuretics, raloxifene hydrochloride, lithium, estrogens and progestins for hormone replacement therapy,methotrexate, or systemic corticosteroids within respective prohibited periods~* Previous treatment with PTH-like drugs, including PTH(1-84), PTH(1-34) or other N-terminal fragments or analogs of PTH or PTH-related protein within 6 months prior to screening~* Other drugs known to influence calcium and bone metabolism, such as calcitonin, fluoride tablets, or cinacalcet hydrochloride within the prohibited period~* Use of oral bisphosphonates within the previous 6 months or IV bisphosphonate preparations within the previous 12 months prior to screening~* Seizure disorder/epilepsy with a history of a seizure within the previous 6 months prior to screening~* Presence of open epiphyses~* Irradiation (radiotherapy) to the skeleton within 5 years~* Serum 25-hydroxyvitamin D levels greater than 1.5-fold the laboratory upper limit of normal~* Participation in any other investigational trial in which receipt of investigational drug or device occurred within 6 months prior to screening for this study~* Pregnant or lactating women~* History of diagnosed drug or alcohol dependence within the previous 3 years~* Clinical history of renal calculi within the past 12 months~* History of gout~* Disease processes that may adversely affect gastrointestinal absorption, including but not limited to short bowel syndrome, bowel resection, tropical sprue, celiac disease, ulcerative colitis, and Crohn's disease~* Chronic/severe cardiac disease including but not limited to cardiac insufficiency, arrhythmias, bradycardia (resting heart rate \< 60 beats/minute), or hypotension (systolic and diastolic blood pressures \< 100 and 60 mmHg, respectively)~* History of cerebrovascular accident (CVA).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Sterile water for injection
- 50, 75, 100 mcg NPSP558 (Type: EXPERIMENTAL): Initial dose of 50mcg, to be titrated up to 75mcg and then 100mcg dependent upon response

Based on this trial design, predict the completion outcome and termination type (if applicable).